154 related articles for article (PubMed ID: 36634212)
41. Distinct apoptotic signaling characteristics of the anti-CD40 monoclonal antibody dacetuzumab and rituximab produce enhanced antitumor activity in non-Hodgkin lymphoma.
Lewis TS; McCormick RS; Emmerton K; Lau JT; Yu SF; McEarchern JA; Grewal IS; Law CL
Clin Cancer Res; 2011 Jul; 17(14):4672-81. PubMed ID: 21610152
[TBL] [Abstract][Full Text] [Related]
42. The Antitumor Activity of IMGN529, a CD37-Targeting Antibody-Drug Conjugate, Is Potentiated by Rituximab in Non-Hodgkin Lymphoma Models.
Hicks SW; Lai KC; Gavrilescu LC; Yi Y; Sikka S; Shah P; Kelly ME; Lee J; Lanieri L; Ponte JF; Sloss CM; Romanelli A
Neoplasia; 2017 Sep; 19(9):661-671. PubMed ID: 28753442
[TBL] [Abstract][Full Text] [Related]
43. Establishing SCID mouse models of B-cell non-Hodgkin's lymphoma.
Yan JS; Chen XY; Li WP; Yang Y; Song ZL
Ai Zheng; 2009 Feb; 28(2):181-3. PubMed ID: 19550134
[TBL] [Abstract][Full Text] [Related]
44. Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma.
Dornan D; Bennett F; Chen Y; Dennis M; Eaton D; Elkins K; French D; Go MA; Jack A; Junutula JR; Koeppen H; Lau J; McBride J; Rawstron A; Shi X; Yu N; Yu SF; Yue P; Zheng B; Ebens A; Polson AG
Blood; 2009 Sep; 114(13):2721-9. PubMed ID: 19633198
[TBL] [Abstract][Full Text] [Related]
45. CD74: a new candidate target for the immunotherapy of B-cell neoplasms.
Stein R; Mattes MJ; Cardillo TM; Hansen HJ; Chang CH; Burton J; Govindan S; Goldenberg DM
Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5556s-5563s. PubMed ID: 17875789
[TBL] [Abstract][Full Text] [Related]
46. Preclinical Characterization of an Antibody-Drug Conjugate Targeting CS-1 and the Identification of Uncharacterized Populations of CS-1-Positive Cells.
Chen R; Rajan S; Overstreet MG; Hurt EM; Thomas SB; Muniz-Medina V; Ward C; Sadowska A; Fleming R; Karanth S; Breen S; Zheng B; Wu Y; Iverson WO; Novick S; O'Day T; Shah DP; Dimasi N; Tiberghien AC; Osbourn J; Walker J
Mol Cancer Ther; 2020 Aug; 19(8):1649-1659. PubMed ID: 32404408
[TBL] [Abstract][Full Text] [Related]
47. Dual-targeting immunotherapy of lymphoma: potent cytotoxicity of anti-CD20/CD74 bispecific antibodies in mantle cell and other lymphomas.
Gupta P; Goldenberg DM; Rossi EA; Cardillo TM; Byrd JC; Muthusamy N; Furman RR; Chang CH
Blood; 2012 Apr; 119(16):3767-78. PubMed ID: 22271448
[TBL] [Abstract][Full Text] [Related]
48. Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma.
Davids MS; Roberts AW; Seymour JF; Pagel JM; Kahl BS; Wierda WG; Puvvada S; Kipps TJ; Anderson MA; Salem AH; Dunbar M; Zhu M; Peale F; Ross JA; Gressick L; Desai M; Kim SY; Verdugo M; Humerickhouse RA; Gordon GB; Gerecitano JF
J Clin Oncol; 2017 Mar; 35(8):826-833. PubMed ID: 28095146
[TBL] [Abstract][Full Text] [Related]
49. Milatuzumab-SN-38 conjugates for the treatment of CD74+ cancers.
Govindan SV; Cardillo TM; Sharkey RM; Tat F; Gold DV; Goldenberg DM
Mol Cancer Ther; 2013 Jun; 12(6):968-78. PubMed ID: 23427296
[TBL] [Abstract][Full Text] [Related]
50. IMGN853, a Folate Receptor-α (FRα)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors.
Ab O; Whiteman KR; Bartle LM; Sun X; Singh R; Tavares D; LaBelle A; Payne G; Lutz RJ; Pinkas J; Goldmacher VS; Chittenden T; Lambert JM
Mol Cancer Ther; 2015 Jul; 14(7):1605-13. PubMed ID: 25904506
[TBL] [Abstract][Full Text] [Related]
51. Phase I Study of a CD45-Targeted Antibody-Radionuclide Conjugate for High-Risk Lymphoma.
Cassaday RD; Press OW; Pagel JM; Rajendran JG; Gooley TA; Fisher DR; Holmberg LA; Miyaoka RS; Sandmaier BM; Green DJ; Gopal AK
Clin Cancer Res; 2019 Dec; 25(23):6932-6938. PubMed ID: 31481510
[TBL] [Abstract][Full Text] [Related]
52. Brentuximab vedotin for treatment of non-Hodgkin lymphomas: A systematic review.
Berger GK; McBride A; Lawson S; Royball K; Yun S; Gee K; Bin Riaz I; Saleh AA; Puvvada S; Anwer F
Crit Rev Oncol Hematol; 2017 Jan; 109():42-50. PubMed ID: 28010897
[TBL] [Abstract][Full Text] [Related]
53. Targeting the CD20 and CXCR4 pathways in non-hodgkin lymphoma with rituximab and high-affinity CXCR4 antagonist BKT140.
Beider K; Ribakovsky E; Abraham M; Wald H; Weiss L; Rosenberg E; Galun E; Avigdor A; Eizenberg O; Peled A; Nagler A
Clin Cancer Res; 2013 Jul; 19(13):3495-507. PubMed ID: 23637121
[TBL] [Abstract][Full Text] [Related]
54. LGR5-Targeted Antibody-Drug Conjugate Eradicates Gastrointestinal Tumors and Prevents Recurrence.
Gong X; Azhdarinia A; Ghosh SC; Xiong W; An Z; Liu Q; Carmon KS
Mol Cancer Ther; 2016 Jul; 15(7):1580-90. PubMed ID: 27207778
[TBL] [Abstract][Full Text] [Related]
55. Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma.
Fanale MA; Younes A
Drugs; 2007; 67(3):333-50. PubMed ID: 17335294
[TBL] [Abstract][Full Text] [Related]
56. Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma.
Panowski SH; Kuo TC; Zhang Y; Chen A; Geng T; Aschenbrenner L; Kamperschroer C; Pascua E; Chen W; Delaria K; Farias S; Bateman M; Dushin RG; Chin SM; Van Blarcom TJ; Yeung YA; Lindquist KC; Chunyk AG; Kuang B; Han B; Mirsky M; Pardo I; Buetow B; Martin TG; Wolf JL; Shelton D; Rajpal A; Strop P; Chaparro-Riggers J; Sasu BJ
Mol Cancer Ther; 2019 Nov; 18(11):2008-2020. PubMed ID: 31434693
[TBL] [Abstract][Full Text] [Related]
57. The novel CD19-targeting antibody-drug conjugate huB4-DGN462 shows improved anti-tumor activity compared to SAR3419 in CD19-positive lymphoma and leukemia models.
Hicks SW; Tarantelli C; Wilhem A; Gaudio E; Li M; Arribas AJ; Spriano F; Bordone R; Cascione L; Lai KC; Qiu Q; Taborelli M; Rossi D; Stussi G; Zucca E; Stathis A; Sloss CM; Bertoni F
Haematologica; 2019 Aug; 104(8):1633-1639. PubMed ID: 30733273
[TBL] [Abstract][Full Text] [Related]
58. Antibody-drug conjugates targeted to CD79 for the treatment of non-Hodgkin lymphoma.
Polson AG; Yu SF; Elkins K; Zheng B; Clark S; Ingle GS; Slaga DS; Giere L; Du C; Tan C; Hongo JA; Gogineni A; Cole MJ; Vandlen R; Stephan JP; Young J; Chang W; Scales SJ; Ross S; Eaton D; Ebens A
Blood; 2007 Jul; 110(2):616-23. PubMed ID: 17374736
[TBL] [Abstract][Full Text] [Related]
59. Galiximab (anti-CD80)-induced growth inhibition and prolongation of survival in vivo of B-NHL tumor xenografts and potentiation by the combination with fludarabine.
Hariharan K; Chu P; Murphy T; Clanton D; Berquist L; Molina A; Ho SN; Vega MI; Bonavida B
Int J Oncol; 2013 Aug; 43(2):670-6. PubMed ID: 23764770
[TBL] [Abstract][Full Text] [Related]
60. Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies.
DiJoseph JF; Armellino DC; Boghaert ER; Khandke K; Dougher MM; Sridharan L; Kunz A; Hamann PR; Gorovits B; Udata C; Moran JK; Popplewell AG; Stephens S; Frost P; Damle NK
Blood; 2004 Mar; 103(5):1807-14. PubMed ID: 14615373
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
